Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
== Application == B1H system provides a tool in our arsenal for identifying the DNA-binding specificities of transcription factors and thus predicting their target genes and genomic DNA regulatory elements. It also allows for examination of the effects of protein–protein interactions on DNA binding, which may further guide the prediction of cis regulatory modules based on binding-site clustering. Moreover, the B1H selection system has implications for the predicting regulatory roles of previously uncharacterized transcription factors.
== Effects on Animals == Calciseptine has been examined in vivo and in vitro in all kinds of animals, but mostly in rats. Calciseptine relaxes precontracted rat (thoracic) aorta and decreases blood pressure drastically. The decrease in blood pressure shows a combination of short- and long-lasting effects. The early, acute onset took five minutes, and the effect could last for 120 minutes or longer. In addition, calciseptine had only a small effect on the heart rhythm, changing it only slightly. Furthermore, it can also relax the trachea rings in the lungs. These effects can be explained by the relaxing activity of calciseptine on various smooth muscle cells. The inhibitory effect of calciseptine results in a decreased or total disappearance of electric activity in these cells. The total inhibitory effect depends on the tissue: the cardiovascular system is the most vulnerable, while neuronal cells are less vulnerable and skeletal muscle cells are completely resistant. This difference in tissue sensitivity is probably caused by slight differences in the L-type calcium channels in these tissues. These effects can occur at low subjected amounts of 0.1 till 1 μM calciseptine. In mouse myotube the Ca2+ currents show higher amplitude after incubation in calciseptine (1 μM). This effect of calciseptine on the Ca2+ current develops relatively fast. Calciseptine changes the reversal potential of the Ca2+ current in mouse myotubes. In adult frog skeletal muscle fibers calciseptine also causes an increased Ca2+ current.
=== Mitochondrial === Three sirtuins, SIRT3, SIRT4 and SIRT5, are located in mitochondria and have been implicated in regulating metabolic processes. Endogenous SIRT3 is a soluble protein located in the mitochondrial matrix. Overexpression of SIRT3 in cultured cells increases respiration and decreases the production of reactive oxygen species. Fasting increases SIRT3 expression in white and brown adipose tissue (WAT and BAT, respectively) and overexpression of SIRT3 in HIB1B brown adipocytes increases the expression of PGC-1α and UCP1, suggesting a role for SIRT3 in adaptive thermogenesis BAT. BAT is different from WAT because it harbors large numbers of mitochondria and is important for thermogenesis in rodents. Thermogenesis in BAT is mediated by the uncoupling protein 1 (UCP1), which induces proton leakage and thereby generates heat instead of ATP. Mechanistic insights into how SIRT3 affects thermogenesis in BAT is lacking and whether SIRT3 affects UCP1 activity directly is not known. In addition to controlling metabolism at the transcriptional level, sirtuins also directly control the activity of metabolic enzymes. In Salmonella enterica, the bacterial sirtuin CobB regulates the activity of the enzyme acetyl-coenzyme A (acetyl-CoA) synthetase. As mentioned above, orthologs of acetyl-CoA synthetase exist in the cytoplasm (AceCS1) and in mitochondria (AceCS2) in mammals. The presence of the sirtuin deacetylase SIRT3 in the mitochondrial matrix suggests the existence of lysine acetylated mitochondrial proteins.
== Development of chromatography == Traditionally, the Cohn process incorporating cold ethanol fractionation has been used for albumin purification. However, chromatographic methods for separation started being adopted in the early 1980s. Developments were ongoing in the time period between when Cohn fractionation started being used, in 1946, and when chromatography started being used, in 1983. In 1962, the Kistler & Nistchmann process was created which was a spinoff of the Cohn process. Chromatographic processes began to take shape in 1983. In the 1990s, the Zenalb and the CSL Albumex processes were created which incorporated chromatography with a few variations. The general approach to using chromatography for plasma fractionation for albumin is: recovery of supernatant I, delipidation, anion exchange chromatography, cation exchange chromatography, and gel filtration chromatography. The recovered purified material is formulated with combinations of sodium octanoate and sodium N-acetyl tryptophanate and then subjected to viral inactivation procedures, including pasteurisation at 60 °C. This is a more efficient alternative than the Cohn process for four main reasons: 1) smooth automation and a relatively inexpensive plant was needed, 2) easier to sterilize equipment and maintain a good manufacturing environment, 3) chromatographic processes are less damaging to the albumin protein, and 4) a more successful albumin end result can be achieved.
=== New Zealand === The opposition Green Party of Aotearoa New Zealand's co-leader, Marama Davidson, stated "this is a unilateral attack that goes against any enduring pathway to international peace through justice." She called upon Prime Minister Christopher Luxon to condemn the United States for attacking Venezuela.
Sources: en.wikipedia.org
Clot-dissolving agents (tissue plasminogen activator) Maggot larval debridement Correction of the underlying plasma calcium and phosphorus abnormalities (lowering the Ca x P product below 55 mg2/dL2) Avoiding further local tissue trauma (including avoiding all subcutaneous injections, and all not-absolutely-necessary infusions and transfusions) Patients who have received kidney transplants also receive immunosuppression. Considering lowering the dose of or discontinuing the use of immunosuppressive drugs in people who have received kidney transplants and continue to have persistent or progressive calciphylactic skin lesions can contribute to an acceptable treatment of calciphylaxis. A group in 2013 reported plasma exchange effective and proposed a serum marker and perhaps a mechanistic mediator (calciprotein)
Humans express two distinct isozymes of IMPDH encoded by two distinct genes, IMPDH1 and IMPDH2. Both isozymes contain 514 residues, have an 84% similarity in peptide sequence, and have similar kinetic properties. Both isozymes are constitutively expressed in most tissues, but IMPDH1 is predominately expressed in the spleen, retina, and peripheral blood leukocytes. IMPDH1 is generally expressed constitutively at low levels, and IMPDH2 is generally upregulated in proliferating cells and neoplastic tissues. Homozygous IMPDH1 knockout mice demonstrate a mild retinopathy in which a slow, progressive form of retinal degeneration gradually weakens visual transduction, while homozygous IMPDH2 knockout mice display embryonic lethality.
==== Revolts of the era of the Spring of Nations ==== The planned national uprising failed to materialize because the authorities in the partitions found out about secret preparations. The Greater Poland uprising ended in a fiasco in early 1846. In the Kraków uprising of February 1846, patriotic action was combined with revolutionary demands, but the result was the incorporation of the Free City of Cracow into the Austrian Partition. The Austrian officials took advantage of peasant discontent and incited villagers against the noble-dominated insurgent units. This resulted in the Galician slaughter of 1846, a large-scale rebellion of serfs seeking relief from their post-feudal condition of mandatory labor as practiced in folwarks. The uprising freed many from bondage and hastened decisions that led to the abolition of Polish serfdom in the Austrian Empire in 1848. A new wave of Polish involvement in revolutionary movements soon took place in the partitions and in other parts of Europe in the context of the Spring of Nations revolutions of 1848 (e.g. Józef Bem's participation in the revolutions in Austria and Hungary). The 1848 German revolutions precipitated the Greater Poland uprising of 1848, in which peasants in the Prussian Partition, who were by then largely enfranchised, played a prominent role.
In May 1986, the company test marketed the concept by selling through grocery stores in Denver and Indianapolis. By the following year, the test was expanded to include Columbus, Ohio, and Portland, Oregon. By 2014, retail sales were eventual expanded to all 50 states with sales conducted through supermarkets, c-stores, vending machines, concessions, military, drug, club, mass and dollar stores. Frozen White Castle hamburgers became available to Canadians in 2015 through various convenience stores and later became available at Canadian Walmart stores in 2018.
Sources: en.wikipedia.org
In botany, apical dominance is the phenomenon whereby the main, central stem of the plant is dominant over (i.e., grows more strongly than) other side stems; on a branch the main stem of the branch is further dominant over its own side twigs. Plant physiology describes apical dominance as the control exerted by the terminal bud (and shoot apex) over the outgrowth of lateral buds.
The centrifugal partition chromatograph instrument is constituted with a unique rotor which contains the column. This rotor rotates on its central axis (while HSCCC column rotates on its planetary axis and simultaneously rotates eccentrically about another solar axis). With less vibrations and noise, the CPC offers a typical rotation speed range from 500 to 2000 rpm. Contrary to hydrodynamic CCC, the rotation speed is not directly proportional to the retention volume ratio of the stationary phase. Like DCCC, CPC can be operated in either descending or ascending mode, where the direction is relative to the force generated by the rotor rather than gravity. A redesigned CPC column with larger chambers and channels has been named centrifugal partition extraction (CPE). In the CPE design, faster flow rates and increased column loading can be achieved.
Loading buffers often contain anionic dyes that are visible under the visible light spectrum, and are added to the gel before the nucleic acid. Tracking dyes should not be reactive so as not to alter the sample, and move down the gel with the DNA or RNA sample. Commonly used color markers include Bromophenol blue, Cresol Red, Orange G and Xylene cyanol. Xylene and bromophenol blue are the most commonly used dyes. Generally speaking, Orange G migrates faster than bromophenol blue, which migrates faster than xylene cyanol, but the apparent "sizes" of these dyes (compared to DNA molecules) varies with the concentration of agarose and the buffer system used. For instance, in a 1% agarose gel made in TAE buffer (Tris-acetate-EDTA), xylene cyanol migrates at the speed of a 3000 base pair (bp) molecule of DNA and bromophenol blue migrates at 400 bp. However, in a 1% gel made in TBE buffer (Tris-borate-EDTA), they migrate at 2000 bp and 250 bp respectively.
The Copenhagen physicists then started a campaign to re-award priority for element 71 to Welsbach and replace the name lutetium with cassiopeium, writing to Welsbach in 1923 of their intentions. This campaign encountered success in the physics literature, but in spite of strong German and Scandinavian support for cassiopeium, lutetium remained embedded in most of the chemical literature, with the International Commission on Atomic Weights in 1930 accepting that element 72 was hafnium but using lutetium for element 71. In 1949, it was decided by the International Union of Pure and Applied Chemistry to recommend the name lutetium, since cassiopeium by then was only used in German and sometimes Dutch, and it was a difficult name to adapt to other languages. It was nonetheless clarified that this was not intended as a statement on priority. Urbain's spelling lutecium was changed to lutetium, in order to derive the name from Latin Lutetia instead of French Lutèce. Pure lutetium metal was first produced in 1953.
== Further reading == Lebovitz, Harold E. (2004). Therapy For Diabetes Mellitus and Related Disorders (4th ed.). Alexandria, VA: American Diabetes Association. ISBN 978-1-58040-187-6. Adams, Michael Ian, Holland, Norman Norwood (2003). Core Concepts in Pharmacology. Englewood Cliffs, NJ: Prentice Hall. ISBN 978-0-13-089329-1.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.